RETRA hydrochlorideAntitumor agent CAS# 1036069-26-7 |
- Nutlin-3a chiral
Catalog No.:BCC1812
CAS No.:675576-98-4
- p53 and MDM2 proteins-interaction-inhibitor chiral
Catalog No.:BCC1830
CAS No.:939981-37-0
- p53 and MDM2 proteins-interaction-inhibitor racemic
Catalog No.:BCC1831
CAS No.:939983-14-9
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 1036069-26-7 | SDF | Download SDF |
| PubChem ID | 46861546 | Appearance | Powder |
| Formula | C11N11NO3S2 | M.Wt | 412.3 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble in DMSO > 10 mM | ||
| Chemical Name | 2-(4,5-dihydro-1,3-thiazol-2-ylsulfanyl)-1-(3,4-dihydroxyphenyl)ethanone;hydrochloride | ||
| SMILES | C1CSC(=N1)SCC(=O)C2=CC(=C(C=C2)O)O.Cl | ||
| Standard InChIKey | ZZAVDVMJZKDBIB-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C11H11NO3S2.ClH/c13-8-2-1-7(5-9(8)14)10(15)6-17-11-12-3-4-16-11;/h1-2,5,13-14H,3-4,6H2;1H | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
RETRA hydrochloride Dilution Calculator
RETRA hydrochloride Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.4254 mL | 12.1271 mL | 24.2542 mL | 48.5084 mL | 60.6355 mL |
| 5 mM | 0.4851 mL | 2.4254 mL | 4.8508 mL | 9.7017 mL | 12.1271 mL |
| 10 mM | 0.2425 mL | 1.2127 mL | 2.4254 mL | 4.8508 mL | 6.0635 mL |
| 50 mM | 0.0485 mL | 0.2425 mL | 0.4851 mL | 0.9702 mL | 1.2127 mL |
| 100 mM | 0.0243 mL | 0.1213 mL | 0.2425 mL | 0.4851 mL | 0.6064 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
IC50: Inhibit tumor cells growth with an IC50of about 4 M.
Being defective for the tumor-suppressor function, mutant p53, a major contributor to malignancy, exerts oncogenic activity also by blocking another tumor-suppressing protein - p73. RETRA hydrochloride is considered to restore mutant p53 activity and therefore to inhibit growth of carcinoma cells. This small molecular could also transcriptionally up-regulates the expression of p53-responsive gene and induces the activation of caspases 3 and 7. RETRA’s anticancer activity is restricted to tumor cells bearing mutant p53. [1]
In vitro: Ewing’s sarcoma (ES) cells with mutant p53 were explored to RETRA, it was found that this compound could substantially up-regulate the expression level of p73 and therefore increase the apoptosis of tumor cells in three mutant p53 ES cell lines. In addition, RETRA was described to activate a set of p53-regulated genes in vitro. However, for most of the p53-deficient carcinoma, osteosarcoma and leukaemia cells, RETRA had no significant effect. [1, 2]
In vivo: Effect of RETRA hydrochloride was studied in vivo using mouse xenografts model. It was noticed that mutant p53-bearing tumor cells were specifically suppressed with a significantly increase in the p73 level and a release of p73 from the blocking complex with mutant p53. [1]
Clinical trial: So far, no clinical study has been conducted.
References:
[1] Kravchenko JE, Ilyinskaya GV, Komarov PG, Agapova LS, Kochetkov DV, Strom E, Frolova EI, Kovriga I, Gudkov AV, Feinstein E, Chumakov PM. Small molecular RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway. PNAS. 2008 Apr; 105(17): 6302–7.
[2] Sonnemann J, Grauel D, Blumel L, Hentschel J, Marx C, Blumrich A, Focke K, Becker S, Wittig S, Schinkel S, Kramer OH, Beck JF. RETRA exerts anticancer activity in Ewing’s sarcoma cells independent of their TP53 status. EUR J CANCER. 2015 Feb; 51:841-851.
- 5,7-Dimethoxyflavanone
Catalog No.:BCN3569
CAS No.:1036-72-2
- Isookanin
Catalog No.:BCN6476
CAS No.:1036-49-3
- P005672 hydrochloride
Catalog No.:BCC6406
CAS No.:1035979-44-2
- Lansoprazole
Catalog No.:BCC1058
CAS No.:103577-45-3
- TAK-733
Catalog No.:BCC4587
CAS No.:1035555-63-5
- 3,7-O-Diacetylpinobanksin
Catalog No.:BCN5849
CAS No.:103553-98-6
- Huperzine B
Catalog No.:BCN1059
CAS No.:103548-82-9
- Apiosylskimmin
Catalog No.:BCN2455
CAS No.:103529-94-8
- AZD4547
Catalog No.:BCC3711
CAS No.:1035270-39-3
- AZ505 ditrifluoroacetate
Catalog No.:BCC4265
CAS No.:1035227-44-1
- AZ505
Catalog No.:BCC4264
CAS No.:1035227-43-0
- Phyllanthin
Catalog No.:BCN5848
CAS No.:10351-88-9
- Janolusimide
Catalog No.:BCN1840
CAS No.:103612-45-9
- H-Phe(2-Cl)-OH
Catalog No.:BCC3165
CAS No.:103616-89-3
- (±)-5'-Chloro-5'-deoxy-ENBA
Catalog No.:BCC7716
CAS No.:103626-26-2
- Sumatriptan
Catalog No.:BCC5645
CAS No.:103628-46-2
- Sumatriptan Succinate
Catalog No.:BCC2502
CAS No.:103628-48-4
- Cnidimol A
Catalog No.:BCN7167
CAS No.:103629-80-7
- Catechin 3-rhamnoside
Catalog No.:BCN5850
CAS No.:103630-03-1
- Ondansetron hydrochloride dihydrate
Catalog No.:BCC4213
CAS No.:103639-04-9
- 2-Carbamoyl-3-hydroxy-1,4-naphthoquinone
Catalog No.:BCC8567
CAS No.:103646-20-4
- Mirificin
Catalog No.:BCN2783
CAS No.:103654-50-8
- Dihydrobonducellin
Catalog No.:BCN3731
CAS No.:103680-87-1
- YK-4-279
Catalog No.:BCC2065
CAS No.:1037184-44-3
